Evolent Health, Inc (EVH)

From the record

Evolent Health, Inc's filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2019-04-10) (its current reports).

From the record

Evolent Health, Inc's 10 filed years say what it did: revenue went from $254 million in fiscal 2016 to $1.9 billion in fiscal 2025, up 24.9% a year; it rose in 7 of 9 years; the deepest fall was 27% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Evolent Health, Inc's diluted share count grew about 6.8% a year, and dividends and buybacks returned about 20% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale (1 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-09-30, buying about $38 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Evolent Health, Inc lost about 129 cents for every dollar of shareholders' money, and gross profitability: its products earned about 21 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 78 cents per dollar of assets, and net share issuance: its share count shrank 0.4% over the year (the filed statements).

From the record

Evolent Health, Inc's standing among 14 graded names in its industry family: revenue of $1.9 billion in fiscal 2025 ranks in the top 50% by size; a net margin of -28.5% ranks in the bottom 32%; revenue growth of 11.5% a year over the last 3 filed years ranks in the top 46% (its annual reports).

From the record

Evolent Health, Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Blackley, Seth (Chief Executive Officer, as filed), filing under that title since 2021-03-03, 5.7 years (top 25% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 3.8 years (bottom 36%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Evolent Health, Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $152 million against debt of $971 million leaves -43.1% of its assets as net cash, bottom 4% of its family; cash from operations less capital spending is 2.1% of revenue (bottom 39%); a gross margin of 21.3% (bottom 13%) (its annual report).

From the record

Evolent Health, Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 11.5% a year over the last three filed years against 24.9% over all 10, slowing (bottom 12% of its family); the newest year grew -26.6% (bottom 4%); research spending grew -5.2% a year (bottom 25%); capital spending grew 31.8% a year (top 32%) (its annual reports). Evolent Health, Inc reported 2 lines of business in fiscal 2025: Reportable at $1.9 billion, Evolent Health Services at $1.9 billion. 0 of 2 grew in the latest filed year, and the largest line is 50% of revenue (its annual report).

From the record

Evolent Health, Inc's newest year against its own record: revenue of $1.9 billion in fiscal 2025 came in 46.6% below the $3.5 billion its prior three years' pace pointed to (bottom 4% of its family); net income of $535 million against a prior three-year average of $65 million (bottom 8%); a net margin of -28.5% against -3.2% before (bottom 13%) (its annual reports).